[3-fluorosulfanyl-4-[6-(methanesulfonamido)-3-oxo-1,2-dihydroinden-5-yl]phenyl] thiohypofluorite - patents, research & applications

36Patents

36Research papers

1Patents - last 3 years

0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Perrigo Pharma International DAC	12
2	Alkermes Pharma Ireland Ltd	10
3	Glaxo Group Ltd	4
4	Nicox SA	1
5	SmithKline Beecham Corp	1

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61K`	Medicinal preparations	34
2	`A61P`	Therapeutic activity (drug indications)	34
3	`B82Y`	Nanotechnology	3
4	`A61F`		1
5	`B23K`		1

6	`C07C`	Acyclic and carbocyclic compounds	1
7	`C07D`	Heterocyclic compounds	1
8	`C07J`		1
9	`C07K`	Peptides	1

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Jane A. Mitchell	Royal Brompton Hospital	4
2	Paola Patrignani	University of Chieti-Pescara	4
3	Chi-Chung Chan	Merck Canada Inc. (Canada)	3
4	Daniel Guay	Merck Canada Inc. (Canada)	3
5	Giovanna Santini	University of Chieti-Pescara	3

6	Maria G. Sciulli	University of Chieti-Pescara	3
7	Robert J. Gordon	Merck Canada Inc. (Canada)	3
8	Anita Greco	University of Chieti-Pescara	2
9	Asokumar Buvanendran	Marymount University	2
10	Carlo Patrono	University of Chieti-Pescara	2

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.	1995	314	Inflammatory mediators and NSAID effects
Effects of inhibition of prostaglandin endoperoxide synthase‐2 in chronic gastro‐intestinal ulcer models in rats	1998	286	Helicobacter pylori-related gastroenterology studies
Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids	2009	117	Pain Mechanisms and Treatments
Effects of the novel anti‐inflammatory compounds, N‐[2‐(cyclohexyloxy)‐4‐nitrophenyl] methanesulphonamide (NS‐398) and 5‐methanesulphonamido‐6‐(2, 4‐difluorothiophenyl)‐1‐indanone (L‐745, 337), on the cyclo‐oxygenase activity of human blood prostaglandin endoperoxide synthases	1995	83	Inflammatory mediators and NSAID effects
Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.	2000	83	Inflammatory mediators and NSAID effects

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of this compound?

The compound has the molecular formula C16H13F2NO3S3 and a molecular weight of 401.4608 g/mol.

Which organizations hold the most patents for this compound?

Perrigo Pharma International DAC holds the most patents with 12 patent filings, followed by Alkermes Pharma Ireland Ltd with 10 patents. Glaxo Group Ltd, Nicox SA, and SmithKline Beecham Corp hold 4, 1, and 1 patents respectively.

What are the primary research topics associated with published work on this compound?

Published research on this compound focuses on topics including inflammatory mediators and NSAID effects, helicobacter pylori-related gastroenterology studies, and pain mechanisms and treatments. Key papers address cyclooxygenase inhibition, prostaglandin endoperoxide synthase activity, and antinociceptive effects during inflammation.

Who are the most prolific authors publishing on this compound and their affiliations?

Jane A. Mitchell from Royal Brompton Hospital and Paola Patrignani from University of Chieti-Pescara are among the most prolific authors, each with 4 papers. Chi-Chung Chan and Daniel Guay from Merck Canada Inc., along with Giovanna Santini, Maria G. Sciulli, and Robert J. Gordon have also published 3 papers each on related research.

What patent classifications are most commonly applied to this compound?

The most frequently used patent classifications are A61K (pharmaceutical preparations) and A61P (pharmaceutical activity classification), each appearing in 34 patents. B82Y (nanotechnology) appears in 3 patents, while A61F, B23K, C07C, C07D, C07J, and C07K each appear in 1 patent.

Who owns the IP

Where innovation is concentrated

Who's driving the science

The literature that defines it

Frequently asked questions

Turn any compound into a complete chemical intelligence landscape